Versartis, Inc. (NASDAQ:VSAR) will issue its quarterly earnings data after the market closes on Thursday, February 16th. Analysts expect the company to announce earnings of ($0.62) per share for the quarter.
Shares of Versartis, Inc. (NASDAQ:VSAR) opened at 15.50 on Wednesday. Versartis, Inc. has a 52 week low of $6.17 and a 52 week high of $16.55. The stock has a 50 day moving average of $14.87 and a 200-day moving average of $13.10. The firm’s market capitalization is $539.32 million.
“Versartis, Inc. (VSAR) to Release Quarterly Earnings on Thursday” was originally published by sleekmoney and is the property of of sleekmoney. If you are accessing this report on another site, it was illegally copied and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at http://sleekmoney.com/versartis-inc-vsar-to-release-quarterly-earnings-on-thursday/1662339.html.
In related news, CFO Joshua T. Brumm sold 3,021 shares of the stock in a transaction dated Wednesday, December 7th. The shares were sold at an average price of $13.25, for a total transaction of $40,028.25. Following the completion of the sale, the chief financial officer now owns 65,814 shares in the company, valued at approximately $872,035.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Perceptive Advisors Llc bought 47,375 shares of the company’s stock in a transaction that occurred on Thursday, December 29th. The shares were purchased at an average price of $14.37 per share, with a total value of $680,778.75. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 381,964 shares of company stock valued at $5,508,950 and have sold 96,433 shares valued at $1,391,291. Company insiders own 11.60% of the company’s stock.
A number of equities analysts have recently issued reports on VSAR shares. Credit Suisse Group upgraded shares of Versartis from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $11.00 to $20.00 in a research note on Tuesday, December 20th. Canaccord Genuity set a $28.00 price objective on shares of Versartis and gave the company a “buy” rating in a research note on Wednesday, November 9th. Zacks Investment Research upgraded shares of Versartis from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a research note on Friday, January 6th. SunTrust Banks, Inc. started coverage on shares of Versartis in a research note on Thursday, December 1st. They issued a “buy” rating and a $25.00 price objective for the company. Finally, Piper Jaffray Companies set a $22.00 price objective on shares of Versartis and gave the company a “buy” rating in a research note on Saturday, January 21st. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $22.50.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/versartis-inc-vsar-to-release-quarterly-earnings-on-thursday/1662339.html
Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.